DO
NBIX icon

denkapparat Operations’s Neurocrine Biosciences NBIX Stock Holding History

denkapparat Operations’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$766K Buy
5,814
+3,240
+126% +$430K 0.32% 116
2025
Q4 		$365K Hold
2,574
– – 0.2% 205
2025
Q3 		$361K Hold
2,574
– – 0.23% 174
2025
Q2 		$324K Hold
2,574
– – 0.26% 162
2025
Q1 		$285K Buy
2,574
+488
+23% +$61.8K 0.3% 141
2024
Q4 		$285K Buy
+2,086
New +$258K 0.42% 99

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

denkapparat Operations's NBIX Position: Q1 2026 in Review

denkapparat Operations increased its Neurocrine Biosciences (NBIX) stake by 126% in Q1 2026, buying an estimated $430K and bringing the position to 5,814 shares worth $766K. The position accounts for 0.32% of the portfolio, ranked #116.

denkapparat Operations first reported a position in NBIX in Q4 2024 and has held it in 6 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • denkapparat Operations held 5,814 shares of Neurocrine Biosciences worth $766K as of Q1 2026.
  • denkapparat Operations bought 3,240 Neurocrine Biosciences shares in Q1 2026, an estimated $430K.
  • Neurocrine Biosciences made up 0.32% of denkapparat Operations's portfolio in Q1 2026, its #116 holding.
  • denkapparat Operations first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 6 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on denkapparat Operations's 13F filing for Q1 2026, filed 11 May 2026.